[HTML][HTML] Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
Glioblastoma multiforme (GBM) is a highly aggressive malignant primary tumor in the central
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
M Rahban, S Joushi, H Bashiri, L Saso… - Frontiers in …, 2024 - ui.adsabs.harvard.edu
Glioblastoma multiforme (GBM) is a highly aggressive malignant primary tumor in the central
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
M Rahban, S Joushi, H Bashiri, L Saso… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is a highly aggressive malignant primary tumor in the central
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
[HTML][HTML] Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment
M Rahban, S Joushi, H Bashiri, L Saso… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is a highly aggressive malignant primary tumor in the central
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …
nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery …